Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors.’ The study aims to evaluate the safety and efficacy of ABBV-CLS-579, both as a standalone treatment and in combination with other agents, for patients with advanced tumors. This research is significant as it seeks to establish a new treatment option for patients with limited alternatives.
The study is testing ABBV-CLS-579, an investigational drug, as a monotherapy and in combination with a PD-1 inhibitor and a VEGFR TKI. These treatments are intended to target and manage advanced solid tumors.
The study design is interventional with a non-randomized, sequential model and no masking. Its primary purpose is treatment-focused, aiming to find a safe and effective dosage for the drug.
The study began on June 3, 2020, with primary completion expected in 2025. The last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This update could impact AbbVie’s stock performance positively, as successful results may enhance its oncology portfolio. Investors should watch for developments, especially in comparison to competitors in the oncology space.
The study is ongoing, with further details available on the ClinicalTrials portal.